Literature DB >> 12010204

Five-year outcome of correctable visual impairment: the Blue Mountains Eye Study.

Suriya Foran1, Kathryn Rose, Jie Jin Wang, Sureka Thiagalingam, Paul Mitchell.   

Abstract

This report aims to describe the outcome and socio-economic characteristics of older persons attending the Blue Mountains Eye Study (BMES) with persistent correct-able visual impairment (VI). The BMESI examined 3654 persons aged 49+ during 1992-1994 and re-examined 2335 survivors during 1997-1999 (BMES II). Visual acuity was measured before and after standardized refraction. Participants had correctable VI if their better eye was visually impaired <6/12 before refraction (with distance glasses if worn) and was unimpaired after refraction. In BMES I,274 persons (7.5%) had correctable VI, of whom 127 returned to BMES II. Of this group of 127, 34 had persistent correctable VI and 74 were no longer impaired. Fewer persons with correctable VI returned and more died prior to BMES II, compared to persons with no or non-correctable VI. This study showed that persistent correctable impairment was more frequent with increasing age, among women, in those living alone, using community support services,or with a history of heart disease.

Entities:  

Mesh:

Year:  2002        PMID: 12010204     DOI: 10.1046/j.1442-9071.2002.00511.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  2 in total

1.  Seven-year incidence of uncorrected refractive error among an elderly Chinese population in Shihpai, Taiwan: The Shihpai Eye Study.

Authors:  T-M Kuang; S-Y Tsai; C J-L Liu; Y-C Ko; S-M Lee; P Chou
Journal:  Eye (Lond)       Date:  2016-01-22       Impact factor: 3.775

2.  Prevalence and Associated Factors of Uncorrected Refractive Error in Older Adults in a Population-Based Study in France.

Authors:  Virginie Naël; Gwendoline Moreau; Solène Monfermé; Audrey Cougnard-Grégoire; Anne-Catherine Scherlen; Angelo Arleo; Jean-François Korobelnik; Cécile Delcourt; Catherine Helmer
Journal:  JAMA Ophthalmol       Date:  2019-01-01       Impact factor: 7.389

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.